EVAX
Evaxion A/S
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-25/100
Last price
3.16
▲ 0.01 (0.32%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
3.15
Day high
3.25
Day low
3.14
Volume
35.87K
Market cap
$28.51M
P/E (TTM)
—
52W range
2.77 – 12.15
Trailing performance
Returnvs SPY
1W
-3.36%
-5.3%
1M
+1.28%
+0.1%
3M
-2.77%
-7.3%
6M
-16.84%
-35.0%
YTD
-33.75%
-48.0%
1Y
-41.80%
-58.2%
3Y
-92.41%
-174.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EVAX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.35M
Total on file
Fundamentals
Market cap$28.51M
Enterprise value$19.46M
Revenue (TTM)$7.49M
Gross profit$7.49M
EBITDA$-8.33M
Net income$-8.65M
EPS (TTM)$-1.00
Free cash flow$-5.49M
Total cash$14.00M
Total debt$7.11M
Book value / share$1.14
Shares outstanding9.02M
Float5.68M
Short % of float0.71%
Dividend yield0.00%
Beta (5Y)0.51
Valuation & profitability ratios
Trailing P/E—
Forward P/E-210.67
PEG ratio—
Price / sales—
Price / book2.76
EV / revenue2.60
EV / EBITDA-2.34
Gross margin100.00%
Operating margin-116.02%
Profit margin-115.54%
Return on equity-109.86%
Return on assets-25.97%
Debt / equity74.55
Current ratio5.06
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $7.53M | $3.34M | $73.00K | $0 | +125.1% |
| Operating revenue | $7.53M | $3.34M | $73.00K | $0 | +125.1% |
| Research & development | $9.97M | $10.46M | $11.92M | $17.06M | -4.6% |
| Selling, general & admin | $6.49M | $7.32M | $10.08M | $8.06M | -11.4% |
| Total operating expense | $16.76M | $18.08M | $22.27M | $25.26M | -7.3% |
| Operating income | -$9.23M | -$14.73M | -$22.20M | -$25.26M | +37.3% |
| Net interest income | $1.99M | -$708.00K | -$743.00K | -$785.00K | +381.2% |
| Pre-tax income | -$8.62M | -$11.36M | -$22.91M | -$23.94M | +24.1% |
| Tax provision | -$908.00K | -$788.00K | -$790.00K | -$772.00K | -15.2% |
| Net income | -$7.71M | -$10.57M | -$22.13M | -$23.17M | +27.1% |
| Net income to common | -$7.71M | -$10.57M | -$22.13M | -$23.17M | +27.1% |
| Basic EPS | -1.00 | -10.00 | -40.50 | -49.00 | +90.0% |
| Diluted EPS | -1.00 | -10.00 | -40.50 | -49.00 | +90.0% |
| EBIT | -$7.74M | -$10.39M | -$22.02M | -$23.14M | +25.5% |
| EBITDA | -$7.12M | -$9.79M | -$21.40M | -$22.57M | +27.2% |
| Basic shares | 6.41M | 1.07M | 546.72K | 472.77K | +497.3% |
| Diluted shares | 6.41M | 1.07M | 546.72K | 472.77K | +497.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.23M | $5.95M | $4.18M | $13.18M | — | +290.4% |
| Cash & short-term investments | $23.23M | $5.95M | $4.18M | $13.18M | — | +290.4% |
| Total current assets | $24.90M | $8.77M | $8.35M | $16.98M | — | +184.1% |
| Property, plant & equipment | $3.32M | $3.51M | $4.34M | $4.67M | — | -5.5% |
| Goodwill & intangibles | — | — | — | $0 | $93.00K | — |
| Total assets | $28.41M | $12.48M | $12.89M | $22.02M | — | +127.5% |
| Total current liabilities | $4.26M | $4.37M | $7.08M | $3.76M | — | -2.5% |
| Current debt | $190.00K | $159.00K | $159.00K | $136.00K | — | +19.5% |
| Long-term debt | $5.35M | $8.01M | $8.49M | $7.86M | — | -33.2% |
| Total debt | $7.50M | $10.10M | $10.87M | $10.26M | — | -25.7% |
| Total liabilities | $11.37M | $14.14M | $17.62M | $13.72M | — | -19.6% |
| Retained earnings | -$126.24M | -$118.54M | -$107.97M | -$85.84M | — | -6.5% |
| Shareholder equity | $17.04M | -$1.65M | -$4.73M | $8.30M | — | +1,131.4% |
| Working capital | $20.64M | $4.40M | $1.27M | $13.22M | — | +369.5% |
| Net tangible assets | $17.04M | -$1.65M | -$4.73M | $8.30M | — | +1,131.4% |
| Shares issued | 417.01M | 70.13M | 37.90M | 24.14M | — | +494.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.71M | -$10.57M | -$22.13M | -$23.17M | — | +27.1% |
| Depreciation & amortisation | $615.00K | $607.00K | $615.00K | $571.00K | — | +1.3% |
| Stock-based compensation | $307.00K | $357.00K | $479.00K | $942.00K | — | -14.0% |
| Change in working capital | -$137.00K | $520.00K | $1.56M | -$2.88M | — | -126.3% |
| Operating cash flow | -$6.63M | -$12.94M | -$17.69M | -$25.77M | — | +48.8% |
| Capital expenditure | -$11.00K | — | -$87.00K | -$292.00K | -$1.36M | — |
| Investing cash flow | -$14.00K | -$3.00K | -$93.00K | -$268.00K | — | -366.7% |
| Financing cash flow | $22.41M | $13.13M | $10.69M | $7.85M | — | +70.7% |
| Free cash flow | -$6.64M | -$12.94M | -$17.78M | -$26.07M | — | +48.7% |
| End cash position | $23.23M | $5.95M | $5.58M | $13.18M | — | +290.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $7.49M | $37.00K | — |
| Operating revenue | $0 | $0 | $0 | $7.49M | $37.00K | — |
| Research & development | $2.33M | $2.30M | $2.56M | $3.09M | $2.17M | +1.6% |
| Selling, general & admin | $1.51M | $1.52M | $1.19M | $1.38M | $2.21M | -0.6% |
| Total operating expense | $3.85M | $3.82M | $4.05M | $4.47M | $4.38M | +0.7% |
| Operating income | -$3.85M | -$3.82M | -$4.05M | $3.02M | -$4.34M | -0.7% |
| Net interest income | -$130.00K | -$27.00K | -$750.00K | $1.33M | -$211.00K | -381.5% |
| Pre-tax income | -$3.93M | -$3.85M | -$6.17M | $4.35M | -$5.03M | -2.3% |
| Tax provision | -$204.00K | -$216.00K | -$256.00K | -$265.00K | -$195.00K | +5.6% |
| Net income | -$3.73M | -$3.63M | -$5.92M | $4.62M | -$4.83M | -2.8% |
| Net income to common | -$3.73M | -$3.63M | -$5.92M | $4.62M | -$4.83M | -2.8% |
| Basic EPS | -0.50 | -0.50 | -1.00 | 0.50 | -1.00 | 0.0% |
| Diluted EPS | -0.50 | -0.50 | -1.00 | 0.50 | -1.00 | 0.0% |
| EBIT | -$3.77M | -$3.51M | -$8.29M | $5.71M | -$4.79M | -7.4% |
| EBITDA | -$3.77M | -$3.51M | -$8.29M | $5.71M | -$4.79M | -7.4% |
| Basic shares | 7.46M | 8.34M | 8.22M | 6.36M | 4.83M | -10.6% |
| Diluted shares | 7.46M | 8.34M | 8.22M | 6.36M | 4.83M | -10.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.00M | $18.44M | $23.23M | $10.57M | $14.75M | -24.1% |
| Cash & short-term investments | $14.00M | $18.44M | $23.23M | $10.57M | $14.75M | -24.1% |
| Total current assets | $15.86M | — | $24.90M | — | $18.18M | — |
| Property, plant & equipment | $2.92M | — | $3.32M | — | $3.62M | — |
| Total assets | $19.38M | $23.64M | $28.41M | $29.74M | $22.45M | -18.0% |
| Total current liabilities | $3.13M | — | $4.26M | — | $5.32M | — |
| Current debt | $190.00K | — | $190.00K | — | $184.00K | — |
| Long-term debt | $5.12M | — | $5.35M | — | $9.03M | — |
| Total debt | $7.11M | — | $7.50M | — | $11.28M | — |
| Total liabilities | $9.85M | $10.44M | $11.37M | $13.14M | $16.22M | -5.6% |
| Retained earnings | -$133.60M | -$133.72M | -$126.24M | -$127.32M | -$124.95M | +0.1% |
| Shareholder equity | $9.53M | -$133.72M | $17.04M | -$127.32M | $6.23M | +107.1% |
| Working capital | $12.72M | — | $20.64M | — | $12.86M | — |
| Net tangible assets | $9.53M | -$133.72M | $17.04M | -$127.32M | $6.23M | +107.1% |
| Shares issued | 417.01M | 417.01M | 417.01M | 396.19M | 315.83M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.01 | -0.01 | 0.0% |
| Mar 2026 | -0.01 | -0.01 | 0.0% |
| Dec 2025 | -0.01 | -0.01 | 0.0% |
| Sep 2025 | -0.01 | 0.01 | +200.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.01 | 1 | $0 | -100.0% |
| Next quarter | -0.01 | 1 | $0 | 0.0% |
| Current year | -0.04 | 2 | $0 | -100.0% |
| Next year | -0.02 | 2 | $4.67M | 0.0% |
Analyst targets & ownership
Mean target$11.25
High target$16.00
Low target$9.00
Implied upside256.01%
Analyst count4
ConsensusNONE
Strong buy / Buy1 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders16.15%
Held by institutions9.31%
Institutions holding20
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.24
-2.35% from price
SMA 20
3.20
-1.23% from price
SMA 50
3.13
+1.01% from price
SMA 100
3.30
-4.29% from price
SMA 200
3.67
-13.81% from price
EMA 12
3.21
-1.41% from price
EMA 26
3.19
-0.96% from price
EMA 50
3.20
-1.24% from price
RSI (14)
48.0
Neutral
MACD (12,26,9)
0.01
Hist -0.01
ATR (14)
0.13
4.13% of price
Realised vol 30D
39.3%
Annualised
Bollinger upper
3.37
20, 2σ
Bollinger lower
3.03
20, 2σ
50 / 200 cross
Death
3.13 vs 3.67
Trend bias
Below 200
-13.81%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.93
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
39.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-74.7%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.13
4.13% of price
Beta (reported)
0.51
5Y monthly, from filing
Short interest
Shares short
53.78K
Prior 20.72K
Change vs prior
+159.5%
Shorts adding
% of float
0.71%
Normal
% of shares out
0.60%
Against total outstanding
Days to cover
0.1
Liquid
Float
5.68M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 10, 26 | Jones Trading | INITIATED | — | Buy |
| Mar 9, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Mar 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 30, 25 | Edward Jones | INITIATED | — | Buy |
| Oct 20, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Oct 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 2, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 4, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Feb 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:5
Split dateJan 14, 2025
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-02
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-09-04
Corporate Changes & Voting Matters
6-K · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-08-17
Corporate Changes & Voting Matters
6-K · 2026-08-14
Corporate Changes & Voting Matters
6-K · 2026-07-17
Corporate Changes & Voting Matters
6-K · 2026-07-13
Headlines
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
MT Newswires · 19h ago
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
GlobeNewswire · 5d ago
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
MT Newswires · 12d ago
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
MT Newswires · 14d ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT Newswires · 15d ago
European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
MT Newswires · 19d ago
European Equities Traded in US as ADRs Rise in Wednesday Trading
MT Newswires · 21d ago
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
GlobeNewswire · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.